Clinical Trial Update: Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects [Phase 2]

View source ↗

Summary

This Phase 2 open-label extension study evaluated epratuzumab in Japanese patients with systemic lupus erythematosus and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Epratuzumab (epratuzumab)

Snippet

Sponsor: UCB Pharma | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED